• Mashup Score: 2
    Flashback Foreword: Cytoreductive Surgery for Ovarian Carcinoma and Carboplatin + Paclitaxel in Ovarian Cancer - 9 month(s) ago

    Collection and assembly of data: David R. Spriggs AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to

    Source: ascopubs.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCO_pubs
      ASCO_pubs

      🎉 Celebrating #JCO's 40th: Read the Flashback Foreword by Drs. Fleming and Spriggs to the top-cited #JCO articles, Cytoreductive Surgery for Ovarian Carcinoma (2002) and Carboplatin + Paclitaxel in Ovarian Cancer (2003): https://t.co/oTwTlAsmYz https://t.co/kqadliKHRa

  • Mashup Score: 9
    Targeting Trop-2 as a Cancer Driver - 9 month(s) ago

    Data analysis and interpretation: Emanuela Guerra, Saverio Alberti AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy,

    Source: ascopubs.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCO_pubs
      ASCO_pubs

      🧐 #JCO #UnderstandingThePathway: Trop-2 as a key driver of cancer development. A novel target for next-generation anticancer therapy ➡️ https://t.co/WzU8x5YVTj @saverio_alberti https://t.co/1Cq9FnMkAw

  • Mashup Score: 3
    Zipalertinib in EGFR Exon 20–Mutant Non–Small-Cell Lung Cancer: Drug Development in a Rare but Crowded Setting - 9 month(s) ago

    In the article that accompanies this editorial, Piotrowska et al 3 report on results from a phase I/II trial of zipalertinib, an oral selective tyrosine kinase inhibitor with specific activity against EGFR exon 20 insertion mutations. Although encouraging efficacy with a response rate of around 38.4% was observed, it remains unclear if this represents a meaningf ul incremental advantage over other agents approved and in development in this space. AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

    Source: ascopubs.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCO_pubs
      ASCO_pubs

      📣 #JCO #Editorial: Zipalertinib in #EGFR exon 20 mutant #NSCLC – drug development in a rare but crowded setting 👉 https://t.co/chowjkeOQw #LungCancer #LCSM @CharuAggarwalMD @StephenVLiu https://t.co/wFp8buOO36

  • Mashup Score: 3
    Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology–ASCO Guideline - 9 month(s) ago

    PURPOSE To provide evidence-based recommendations to health care providers on integrative approaches to managing anxiety and depression symptoms in adults living with cancer. METHODS The Society for Integrative Oncology and ASCO convened an expert panel of integrative oncology, medical oncology, radiation oncology, surgical oncology, palliative oncology, social sciences, mind-body medicine, nursing, methodology, and patient advocacy representatives. The literature search included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2023. Outcomes of interest included anxiety or depression symptoms as measured by validated psychometric tools, and adverse events. Expert panel members used this evidence and informal consensus with the Guidelines into Decision Support methodology to develop evidence-based guideline recommendations. RESULTS The literature search identified 110 relevant studies (30 systematic reviews and 80 randomized controlled tri

    Source: ascopubs.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCO_pubs
      ASCO_pubs

      🚨 ICYMI @ASCO-@Integrativeonc #GuidelineUpdate published in #JCO: #IntegrativeOncology Care of #Anxiety and Depressive Symptoms in Adult Patients with Cancer 👉 https://t.co/FSkGhZsVux #psyonc #supponc https://t.co/OD3R2DrpU3

  • Mashup Score: 3
    Cell-Free Circulating Tumor DNA and Epstein-Barr Virus DNA for Early Diagnosis of Epstein-Barr Virus–Associated Cancers - 9 month(s) ago

    AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-ce

    Source: ascopubs.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCO_pubs
      ASCO_pubs

      🧐 #JCO #UnderstandingThePathway: Cell-Free Circulating Tumor DNA and Epstein-Barr Virus DNA for Early Diagnosis of EBV-Associated Cancers ➡️ https://t.co/5nqFru0KQO #NasopharyngealCarcinoma #lymphoma #hncsm #lymsm https://t.co/yY6jhEpt0X

  • Mashup Score: 11
    Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update - 9 month(s) ago

    ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. See the Appendix for disclaimers and other important information (Appendix 1 and Appendix 2, online only).

    Source: ascopubs.org
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of ASCO
      ASCO

      RT @JCO_ASCO: 🚨 @ASCO #JCO #GuidelineUpdate: Management of Stage III Non Small Cell #LungCancer ➡️ https://t.co/LDGjyX1VMF #NSCLC #LCSM @ns…

  • Mashup Score: 6
    Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study - 9 month(s) ago

    The phase III ASPEN study demonstrated the comparable efficacy and improved safety of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia (WM). Here, we report long-term follow-up outcomes from ASPEN. The primary end point was the sum of very good partial response (VGPR) + complete response (CR) rates; secondary and exploratory end points were also reported. Cohort 1 comprised 201 patients (myeloid differentiation primary response 88–mutant WM: 102 receiving zanubrutinib; 99 receiving ibrutinib); cohort 2 comprised 28 patients (myeloid differentiation primary response 88 wild-type WM: 28 zanubrutinib; 26 efficacy evaluable). At 44.4-month median follow-up, VGPR + CR rates were 36.3% with zanubrutinib versus 25.3% with ibrutinib in cohort 1 and 30.8% with one CR in cohort 2. In patients with CXC motif chemokine receptor 4 mutation, VGPR + CR rates were 21.2% with zanubrutinib versus 10.0% with ibrutinib (cohort 1). Median progression-free survival and overall su

    Source: ascopubs.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCO_pubs
      ASCO_pubs

      ✨ #JCO #ClinicalTrialUpdates: Zanubrutinib continues to demonstrate meaningful efficacy and favorable safety in patients with #WaldenströmMacroglobulinemia 👉 https://t.co/NySi1ibcAL #lymsm @thanosdimop https://t.co/2tv0WNCjGD

  • Mashup Score: 7
    Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future - 9 month(s) ago

    Historically, the outcomes for individuals with triple-class refractory and penta-drug refractory multiple myeloma (MM) have been poor because of a dearth of effective treatment options. However, the advent of chimeric antigen receptor (CAR) T-cell and T-cell redirecting bispecific antibody (BsAb) therapies has led to unprecedented response rates and durations of response in heavily relapsed/refractory (R/R) populations. Currently, two B-cell maturation antigen (BCMA)–directed CAR T-cell therapies (idecabtagene vicleucel and ciltacabtagene autoleucel) as well as one BCMA/CD3 BsAb (teclistamab) have been approved for late-line (greater than four previous lines) R/R MM in the United States. The purpose of this review is to analyze the recent data for these approved therapies as well as provide an overview of other related CAR T-cell and BsAb therapies under development, including non–BCMA-targeting agents. We review efficacy and safety considerations, with particular focus on cytokine re

    Source: ascopubs.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCO_pubs
      ASCO_pubs

      🗒️ #JCO #Review: Great hope for the future: CAR T-cell & bispecific antibody therapies in #MultipleMyeloma 👉 https://t.co/jXytpuo1KT #MMSM #ImmunoOnc @DrSarahHolstein @tanyawildes @ShakiraG_MBBS https://t.co/1VyXxSj0jp

Load More